You just read:

Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

News provided by

Jazz Pharmaceuticals plc

27 Jun, 2018, 21:15 BST